Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Metastatic Malignant Melanoma
NCT00098553Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in melanoma, sponsored by Cancer and Leukemia Group B. Primary endpoint: Proportion of patients with progression-free disease at 16 weeks. Started Apr 2005; status: completed.
02
Drugs
everolimus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00098553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098553.